Search Results - "Juretic, M"

312 A Novel Assay for the Met Inhibitory Activity of MGCD265 in Plasma From Solid Tumor Patients in a Dose Escalating Phase I Study by Fournel, M, Wang, J, Beaulieu, N, Bonfils, C, Hurwitz, H, Shapiro, G, Kollmannsberger, C.K, Juretic, M, Besterman, J.M, Maroun, C.R

Get full text

Salivary levels of TNF-α and IL-6 in patients with oral premalignant and malignant lesions by Juretić, M, Cerović, R, Belušić-Gobić, M, Brekalo Pršo, I, Kqiku, L, Špalj, S, Pezelj-Ribarić, S

“…The aim of this study was to determine the salivary concentrations of tumour necrosis factor α (TNF-α) and interleukin 6 (IL-6) in patients with premalignant…”
Get full text

Biopharmaceutical evaluation of surface active ophthalmic excipients using in vitro and ex vivo corneal models by Juretić, Marina, Cetina-Čižmek, Biserka, Filipović-Grčić, Jelena, Hafner, Anita, Lovrić, Jasmina, Pepić, Ivan

“…The objective of this study was to systematically investigate the effects of surface active ophthalmic excipients on the corneal permeation of ophthalmic drugs…”
Get full text

P-757 - Oral and oropharinegeal cancer and defence mechanisms by Petrić, D, Juretić, M, Frančišković, T, Graovac, M, Vučić-Peitl, M

“…Biological mechanisms of tumor development are largely known, however influence of psychological factors in alcoholics with malignant tumor of the oral cavity…”
Get full text

493P - Pharmacokinetic Profile of MGCD265, an Oral Tyrosine Kinase Inhibitor, with or Without Food in Healthy Volunteers by Sicard, E., Juretic, M., Drouin, M., Reid, G., Wang, J., Hunt, W., Maroun, C., Besterman, J.

“…MGCD265 is a novel targeted cancer therapeutic, currently in phase I/II clinical trials, that inhibits Met and VEGF receptor tyrosine kinases. The abnormal…”
Get full text

Pharmacokinetic Profile of MGCD265, an Oral Tyrosine Kinase Inhibitor, with or Without Food in Healthy Volunteers by Sicard, E., Juretic, M., Drouin, M., Reid, G., Wang, J., Hunt, W., Maroun, C., Besterman, J.

Get full text

471P - A Phase I, Dose-Escalation Study of Mgcd265, A Multi-Targeted Oral Tyrosine Kinase Receptor Inhibitor, for Treatment of Advanced Solid Tumors by Hurwitz, H.I., Kollmannsberger, C.K., Juretic, M., Wang, J., Fournel, M., Bonfils, C., Maroun, C., Humphrey, R.W., Besterman, J., Shapiro, G.

“…MGCD265 is a multikinase inhibitor with activity against Met, VEGFR 1, 2 and 3, Tie-2 and Ron that has been shown in preclinical models to possess broad…”
Get full text

A Phase I, Dose-Escalation Study of Mgcd265, A Multi-Targeted Oral Tyrosine Kinase Receptor Inhibitor, for Treatment of Advanced Solid Tumors by Hurwitz, H.I., Kollmannsberger, C.K., Juretic, M., Wang, J., Fournel, M., Bonfils, C., Maroun, C., Humphrey, R.W., Besterman, J., Shapiro, G.

Get full text

The influence of war stress on the prevalence of signs and symptoms of temporomandibular disorders by Uhač, I., Kovač, Z., Valentić-Peruzović, M., Juretić, M., Moro, L. J., Gržić, R.

“…summary  The aim of this study was to determine the prevalence of signs and symptoms of temporomandibular disorders in patients with post‐traumatic stress…”
Get full text

A phase I study of oral administration of MGCD265 in patients with advanced malignancies (study 265-102) by Heath, E. I., LoRusso, P., Kurzrock, R., Falchook, G. S., Maroun, C. R., Drouin, M. A., Juretic, M., Martell, R. E., Besterman, J. M., Wheler, J. J.

“…Abstract only…”
Get full text

Salivary Levels of TNF-[alpha] and IL-6 in Patients with Oral Premalignant and Malignant Lesions by Juretic, M, Cerovic, R, Belusic-Gobic, M, Prso, I Brekalo, Kqiku, L, Spalj, S, Pezelj-Ribaric, S

“…The aim of this study was to determine the salivary concentrations of tumour necrosis factor α (TNF-α) and interleukin 6 (IL-6) in patients with premalignant…”
Get full text

THE PROBLEM OF RUBEOLA EMBRYOPATHIES by JURETIC, M

Get more information

The Care Coordination Home Telehealth (CCHT) rural demonstration project: a symptom-based approach for serving older veterans in remote geographical settings by Luptak, Marilyn, Dailey, Nancy, Juretic, Meghan, Rupper, Randall, Hill, Robert D, Hicken, Bret L, Bair, Byron D

“…Innovative healthcare delivery strategies are needed to address the healthcare needs of the 3.5 million older veterans living in US rural areas who face unique…”
Get full text

Exanthema subitum a review of 243 cases by JURETIC, M

Get more information

Incubation period of primary herpetic infection by JURETIC, M

Get more information

2871 – Capgras syndrome and mignon delusion - delusional misidentification syndromes by Juretić Pešćica, M, Knez, R, Pavešić Radonja, A

“…Introdaction: Delusional misidentification syndromes are specific groups of psychopathological symptoms. In rare cases, can occur independently but are often…”
Get full text

Two different manifestations of locked-in syndrome by Golubovic, V, Muhvic, D, Golubovic, S, Juretic, M, Tokmadzic, V Sotosek

“…Locked-in syndrome (LIS) is an entity that usually occur a consequence of the lesion of ventral part of pons. Etiology of locked-in syndrome can be vascular…”
Get full text

P-1109 - Synergistic effect of some psychopharmacs may lead to an side effect by Pavesic Radonja, A, Juretić Pešćica, M

“…Aim To show that a combination of psychopharmacotherapy can result in unwanted side effect. Method We are presenting a 31-year-old patient addmitted to the…”
Get full text

P-1089 - With psychopharmacs titration to the therapeutic effectiveness and reduction of side effect by Juretić Pešćica, M, Pavesic Radonja, A

“…Aim Describe the possibility that medications without anticipated anticholinergic effects can have that type of side effect. Method We would like to present a…”
Get full text

The Care Coordination Home Telehealth (CCHT) rural demonstration project: A symptom-based approach for serving older veterans in remote geographical settings by M Luptak, N Dailey, M Juretic, R Rupper, R D Hill, B L Hicken, B D Bair

“…Innovative healthcare delivery strategies are needed to address the healthcare needs of the 3.5 million older veterans living in US rural areas who face unique…”
Get full text